TrialClinical drug investigation2024

A Phase I Clinical Trial to Evaluate the Bioequivalence of an Adalimumab Biosimilar Adalimumab-WIBP and Humira

Shengling Hu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.